
Four in Five HF Patients Could Benefit From Dapagliflozin, Registry Study Suggests
A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.
A new study presented today shows that 4 in 5 patients with
The findings, presented during the American Heart Association (AHA) Scientific Sessions and published in
According to a statement from
Dapagliflozin, sold as Farxiga, is part of the SGLT2 inhibitor class that was first developed to treat type 2
The
Although today’s results apply only to dapagliflozin, the authors note that findings for empagliflozin (Jardiance) presented during the European Society of Cardiology in August found similar efficacy in HFrEF, whether or not patients had T2D.
However, the lead author of TRANSLATE-HF and other experts have reported that not all patients who might benefit from SGLT2 inhibitors are receiving them.
“Despite accelerating scientific discoveries, few patients with heart failure are being treated with the best available treatment options in 2020,” lead author Muthiah Vaduganathan MD, MPH, and a cardiologist at Brigham and Women’s Hospital and Harvard Medical School, said in
In addition to showing the missed opportunity to treat more patients with heart failure generally, the results show that better awareness and greater willingness of cardiologists to prescribe SGLT2 inhibitors might help reach women and Black patients, who were less well represented in the DAPA-HF trial.
“Although there were more older adults, women, and Black patients in the [AHA] registry than in the DAPA-HF trial, most clinical characteristics were qualitatively similar between the 2 groups,” the study authors wrote, adding that compared with the DAPA-HF trial population, “there was lower use of evidence-based HF therapies,” among patients in the AHA registry.
Earlier this year,
When cardiologists prescribe SGLT2 inhibitors, McGuire said communicating with other care providers is essential. This “engages the co-providers in a team approach,” so that the other providers understand that “we’re not stepping on their toes and we’re not embarking on glucose management in their clinic, but that we are using these medications for further cardiovascular benefits,” said McGuire.
“These data support the broad generalizability of recent trial findings evaluating the SGLT2 inhibitors to US clinical practice,” said Gregg C. Fonarow, MD, senior author of the study, who is interim chief of the division of cardiology and director of the Ahmanson-UCLA Cardiomyopathy Center, as well as co-director of the Preventative Cardiology Program, and the Eliot Corday Chair in Cardiovascular Medicine and Science at the University of California, Los Angeles. “The SGLT2 inhibitors are now established as a new pillar of care for patients with heart failure. We must now rapidly translate this knowledge to practice to improve patient outcomes.”
Reference
Vaduganathan M, Greene SJ, Zhang S, et al. Applicability of US Food and Drug Administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: he Get With the Guidelines–Heart Failure (GWTG-HF) Registry. JAMA Cardiol. Published online November 13, 2020. doi:10.1001/jamacardio.2020.5864
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.